LU88373A1 - Weight loss product - Google Patents
Weight loss product Download PDFInfo
- Publication number
- LU88373A1 LU88373A1 LU88373A LU88373A LU88373A1 LU 88373 A1 LU88373 A1 LU 88373A1 LU 88373 A LU88373 A LU 88373A LU 88373 A LU88373 A LU 88373A LU 88373 A1 LU88373 A1 LU 88373A1
- Authority
- LU
- Luxembourg
- Prior art keywords
- product
- biochemistry
- components
- weight loss
- company
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
BREVET EUROPEEN D'INVENTION PRODUIT " SILHOUETTE Premier "EUROPEAN PATENT OF INVENTION "SILHOUETTE Premier" PRODUCT
Ingrédients et composition: (par comprimé ou capsule-gel)Ingredients and composition: (per tablet or gel-capsule)
Betaine mg. 55Betaine mg. 55
Vitamine PP (Nicotinamide) mg. 63Vitamin PP (Nicotinamide) mg. 63
Benfluorex HCL mg. 46Benfluorex HCL mg. 46
Papaïne mg. 60Papain mg. 60
Clorazépate-Dipotassique mg. 1,5 DEAD-D (Diéthyl-amino-éthyle Dextrane) HCL mg. 102 Acide Ursodesoxy-cholique mg. 20 L-Carnitine mg. 25 Lécithine mg. 20Clorazepate-Dipotassium mg. 1.5 DEAD-D (Diethyl-amino-ethyl Dextran) HCL mg. 102 Ursodesoxycholic acid mg. 20 L-Carnitine mg. 25 Lecithin mg. 20
Adjuvants de fabrication = cellulose, stéarate de magnesium.Manufacturing aids = cellulose, magnesium stearate.
Poids net par comprimé ou capsule gel = mg. 400 Posologie =Net weight per tablet or gel capsule = mg. 400 Dosage =
Produit en base de Brevet Européen N°......................du Prof. Michel URSO.Product based on European Patent N ° ...................... of Prof. Michel URSO.
Produit de: Laboratoires MEDICAE Mémoire descriptive du produit "SILHOUETTE PREMIER"Product of: MEDICAE Laboratories Descriptive memory of the product "SILHOUETTE PREMIER"
Premier chapitreFirst chapter
Description de l'invention: 1) Le titre de cette invention est "Silhouette Premier". 2) Le domaine technique auquel elle se reporte, est celui est celle de médicament pour maigrir. 3) La technique antérieure comprenait l'emploi des substances unitaires, mais non le mixage éudié par nous, afin d'obtenir le résultat préfixé, sans nuire à la santé, la Bétaine est un Hépato-protecteur.Description of the invention: 1) The title of this invention is "Silhouette Premier". 2) The technical field to which it refers is that of weight loss medicine. 3) The prior art included the use of unitary substances, but not the mixture studied by us, in order to obtain the prefixed result, without harming health, Betaine is a Hepato-protector.
La vitamine PP a une action contre la Lipémie.Vitamin PP has an action against Lipemia.
Le Benfluorex HCL est un hypolipémiant diminuant le cholestérol et les triglycérides, avec une formule de structure = C19 H 20, reconnue par la Pharmacopea Européenne pour son activité positive dans le cas d'obésité, ou trouble du métabolisme lipidique.Benfluorex HCL is a lipid-lowering agent lowering cholesterol and triglycerides, with a structural formula = C19 H 20, recognized by the European Pharmacopea for its positive activity in the case of obesity, or lipid metabolism disorder.
La Papaine est employée pour les troubles dyspeptiques.Papaine is used for dyspeptic disorders.
Le Diéthylamino-éthyle Dextrane - (DEAE - D) HCL à un pouvoir contre la Lipémie.Diethylamino-ethyl Dextran - (DEAE - D) HCL has a power against Lipemia.
Le Clorazépate Dipotassique est un léger remède contre l'anxiété, (anxiolytique non phyprogéne).Clorazepate Dipotassique is a mild remedy for anxiety (non-phyprogenous anxiolytic).
La Carnitine a la propriété de transporter les acides gras à travers la membrane mitochondriale.Carnitine has the property of transporting fatty acids across the mitochondrial membrane.
La Lécithine est une substance lipotrope qui favorise la démolition des graisses -(lipolyse).Lecithin is a lipotropic substance which promotes the demolition of fats - (lipolysis).
Notre étude en milieu clinique a démontré l'efficacité du produit, sans problème pour l'organisme humain, quand sont suivi nos prescriptions. Le produit vient absorbé par la partie gastro-intestinale, avec "émivie " de 15 heures environ. 4) L'objet de la protection demandé, est ia tutelle de la marque du modèle déposé, du nom commercial du produit, de la composition, tel qu'il soit pour le pourcentage, que pour l'union des composants. On demande la tutelle du produit, pour ou contre la mise en commerce, et vente des produits similaires, en concurrence, et contrefaçons.Our clinical study has demonstrated the effectiveness of the product, without problem for the human organism, when our prescriptions are followed. The product is absorbed by the gastrointestinal part, with an "emivie" of about 15 hours. 4) The object of protection requested is the protection of the trademark of the registered model, the commercial name of the product, the composition, as it is for the percentage, as for the union of the components. We ask for the protection of the product, for or against the marketing, and sale of similar products, in competition, and counterfeits.
Les termes précis pour la compréhension du problème technique, sont l'emploie des diverses substances avec la qualité et la quantité des composants, parce que les avantages qu'il donne à l'organisme humain dépendent de l'utilisation des substances telles qu'elles ont été formulées. 5) En ce qui concerne le mode de réalisation, on remarque qu'il consiste à utiliser la formule chimique du produit, selon ia description des ingrédients et leurs compositions. 6) Les possibilités concrètes d'exploitation et d'application industrielle, sont celles de produire un produit avec la même composition, et de la mettre en vente.The precise terms for the understanding of the technical problem, are the use of the various substances with the quality and the quantity of the components, because the benefits which it gives to the human organism depend on the use of the substances such as they have been formulated. 5) As regards the embodiment, it is noted that it consists in using the chemical formula of the product, according to the description of the ingredients and their compositions. 6) The concrete possibilities of exploitation and industrial application are those of producing a product with the same composition, and putting it on sale.
Claims (2)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU88373A LU88373A1 (en) | 1993-07-12 | 1993-07-12 | Weight loss product |
| FR9408548A FR2710245B3 (en) | 1993-07-12 | 1994-07-11 | Slimming composition. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU88373A LU88373A1 (en) | 1993-07-12 | 1993-07-12 | Weight loss product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU88373A1 true LU88373A1 (en) | 1994-04-01 |
Family
ID=19731419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU88373A LU88373A1 (en) | 1993-07-12 | 1993-07-12 | Weight loss product |
Country Status (2)
| Country | Link |
|---|---|
| FR (1) | FR2710245B3 (en) |
| LU (1) | LU88373A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0965278A1 (en) * | 1998-06-16 | 1999-12-22 | Mathias Christian Zohoungbogbo | Dietetic food composition and dietetic method using such composition |
| GB2358135A (en) * | 1999-12-09 | 2001-07-18 | Finnfeeds Int Ltd | Animal feed additives comprising betaine and a protease |
| WO2006007675A1 (en) * | 2004-07-20 | 2006-01-26 | Libbs Farmacêutica Ltda. | Cholic acid and/or its derivatives for the reduction of localized fat in the human body |
| KR101412221B1 (en) * | 2012-08-14 | 2014-06-27 | (주)바이오뉴트리젠 | Composition of antiobesity containing Lycium chinensis leaf extract powder and betaine as effective ingredients |
| EP3400935A1 (en) * | 2017-05-12 | 2018-11-14 | Hospital Sant Joan de Deu | Betaine for the prevention of obesity |
-
1993
- 1993-07-12 LU LU88373A patent/LU88373A1/en unknown
-
1994
- 1994-07-11 FR FR9408548A patent/FR2710245B3/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| FR2710245B3 (en) | 1995-10-13 |
| FR2710245A1 (en) | 1995-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69636783T2 (en) | METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION | |
| Werneburg et al. | TNF-α-mediated lysosomal permeabilization is FAN and caspase 8/Bid dependent | |
| AU691250B2 (en) | Lipophilic carrier preparations | |
| JP4452187B2 (en) | Composition for targeted release of fragrances and aromas | |
| JPS59167512A (en) | Dihydropyridine liquid composition | |
| DE3612538C2 (en) | ||
| CA2330500A1 (en) | Pharmaceutical compositions capable of being gelled | |
| JP6280120B2 (en) | Formulations for delivering nucleic acid sequences capable of modulating the endogenous mechanism of interfering RNA | |
| HUP0100430A2 (en) | Pharmaceutical composition for enhancing the absorption of lipid soluble compounds containing structured glycerides and the use thereof | |
| WO2008064916A2 (en) | Agent for treating vascular leaks | |
| WO2020024598A1 (en) | Hypoallergenic cosmetic composition | |
| LU88373A1 (en) | Weight loss product | |
| DE69723688T2 (en) | CONNECTIONS WITH CYTOPROTECTIVE EFFECT | |
| JP4156841B2 (en) | Topical formulation for transdermal delivery of niacin and method for treating hyperlipidemia | |
| JPS6036408A (en) | Antiinflammatory depot agent | |
| JP3702307B2 (en) | Anti-allergic skin external composition | |
| JPS58206597A (en) | Aqueous phospholipid solution | |
| FI941046A (en) | Pharmaceutical process | |
| DE68907392T2 (en) | Dysmnesia modifying drugs. | |
| Day | The relationship of arterial macrophages to the phospholipid content in rabbit atheroma | |
| Maxwell et al. | Effects of ascorbic acid and EDTA on vascular concentration-response to catecholamines | |
| DE60124516T2 (en) | COMBINATION OF THE LEZITHINE WITH ASCORBIC ACID | |
| JPH07258070A (en) | Nose cleaning agent | |
| EP2421502B1 (en) | Composition comprising glycyrrhetic acid for repairing previously incurred damaged to skin dna | |
| Berkovitz et al. | Observations on the aetiology of supernumerary upper incisors in the albino ferret (Mustela putorius) |